{
  "docId": "019dd923-622c-750b-8b9a-ad0811d3e80d",
  "docSlug": "dfcef8f28a20",
  "documentTitle": "Accelerate Diagnostics (AXDX)",
  "authorId": "61_White_Diamond_Research",
  "authorName": "White Diamond Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2019-09-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 36,
  "pageCount": 41,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 14,
  "notes": "The table compares T2 Biosystems (implied) vs Accelerate Diagnostics (AXDX).",
  "elementsJson": [
    "comparison_table",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-ad0811d3e80d/36",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d#slide-36",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "In a similar way, we predict AXDX share price drop to $6 within 6-9 months of publishing this report.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-78b4-70ad-b3a2-704a428984a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Enterprise Value/Sales: 180X",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-78b4-70ad-b3a2-762cdf164634",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.784,
        "x": 0.108,
        "y": 0.605
      },
      "kind": "paragraph",
      "text": "We first exposed TTOO with a bearish article on 3/5/19... we predict AXDX share price drop to $6 within 6-9 months... The AST story, however, is oversimplified and overhyped.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ad3bed5-f556-4cf5-974c-1f1c4526a5da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.108,
        "y": 0.5
      },
      "kind": "source-note",
      "text": "Source: WDR Research",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ec77b01-a232-46fb-a268-72fb5338267b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.495,
        "w": 0.784,
        "x": 0.108,
        "y": 0.09
      },
      "kind": "table",
      "text": "Comparison of diagnostic testing metrics between two companies.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd2fb3ba-fe42-45d4-bab9-1bcc033d9d69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.784,
        "x": 0.108,
        "y": 0.78
      },
      "kind": "title",
      "text": "BioFire buyout 6 years ago does not justify AXDX’s $1B market valuation",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4a0dcaa-ba9e-4574-979d-20e727223df1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "b211a9cb-ce2e-4846-a0a1-9706f9dad7b9",
      "evidence": "Table comparing two entities across multiple metrics to support a bearish investment thesis.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 41,
      "from": 30,
      "beatId": "ca57db9c-677e-4ef8-919c-92b1690ee48e",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document implies that the solution is to be cautious of the system's limitations and avoid investment in AXDX, citing a potential decline in AXDX shares.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 36,
      "name": "So What Cascade",
      "slug": "41-so-what-cascade",
      "bestFor": "Data presentations, executive summaries, driving to recommendations",
      "matchId": "4a0cc194-140e-4021-ac97-526c652944fe",
      "evidence": "The document presents a cascade of implications, including a potential CEO replacement, market guidance downgrade, and decline in AXDX shares.",
      "position": 2,
      "objective": "So what does this mean for AXDX's future?",
      "structure": "The Data -> So What? (Insight 1) -> So What? (Insight 2) -> So What? (The Action)",
      "confidence": 0.7,
      "description": "Chain insights together, each answering 'so what?' until you reach the actionable conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}